GENE ONLINE|News &
Opinion
Blog

2022-07-25| COVID-19R&D

Monoclonal Antibody Discovered to Potentially Act Against All Coronaviruses

by Fujie Tham
Share To

University of Alabama researchers discovered a potent monoclonal antibody that could act as a universal coronavirus therapy for SARS-CoV-2 and all its variants of concern.

After screening the plasma from subjects recovered from COVID-19, the team found several promising antibodies that target the highly conserved stalk region of the viral spike protein (S) among beta-coronaviruses. The monoclonal antibody designated 1249A8 surfaced to be the most broad-spectrum, recognizing all human beta-coronavirus and neutralizing SARS-CoV and MERS-CoV.

“SARS-CoV-2 has caused the most infections and deaths worldwide. New variants pose the risk of evading the immune system, even in vaccinated and previously infected individuals, and there remains the potential for other genetically distinct coronaviruses to emerge as new pandemic strains in the future,” said co-author James J. Kobie.

Related article: Aridis Pharmaceuticals’ Antibody Shows Early Promise in the Fight Against COVID-19 

 

Antibody 1249A8 Could Guide Universal COVID-19 Vaccine’s Development

 

Besides 1249A8, the team also identified another human monoclonal antibody specific to the receptor-binding domain (S1) of SARS-CoV-2, named 1213H7. When these two antibodies are combined into a nasal therapeutics dose for hamsters, the therapy displayed synergistic activity in neutralizing coronaviruses SARS-CoV-2 Beta, Gamma, Delta, Epsilon, and Omicron variants.

The research suggested that by combining S2 and S1-targeting antibodies, the similarly powerful coronavirus neutralizing antibodies with therapeutic potential can be induced in humans and can inspire future coronavirus vaccine development.

While multiple SARS-CoV-2 receptor-binding domain-specific antibodies have been approved for clinical use (such as casirivimab and imdevimab), several have been unable to neutralize variants of concern such as Omicron. Kobie’s team demonstrated the clear clinical potential of 1249A8 including in combination with 1213H7, and the value of direct nasal therapeutic delivery.

The researchers hope the discoveries will be the answer to SARS-CoV-2’s immune escape caused by frequent mutations, and are being developed into COVID-19 treatments by Aridis Pharmaceuticals into vaccines and self-administered inhaled formulation. Aridis is looking forward to starting its Phase 1 trial for the drug, AR-701 later this year.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
Global Expansion between Europe and India of Novel anti-PD-1 mAb Serplulimab
2023-10-31
U.S. Government Awards $1.4 Billion to Advance COVID Therapies and Vaccines
2023-08-29
LATEST
AI Reveals Sex-Related Brain Differences and Precision Medicine Potential
2024-05-16
The EU Sustainability Directive’s Influence on Pharmaceutical Supply Chains
2024-05-15
New UC Berkeley Study Challenges Traditional Views on Lactate and Carbohydrate Metabolism
2024-05-15
First Person to Receive Transplanted Pig Kidney has Died
2024-05-13
Kexing Biopharm Facility Passes EU GMP Certification for Paclitaxel for Injection (Albumin Bound)
2024-05-10
Biotech in Beauty: Engineered Skin Bacteria Designed To Treat Acne
2024-05-10
Revolutionizing Treatment: ASGCT’s Clinical Trials Spotlight on Immunotherapy, Cancer Vaccines, and Auditory Diseases
2024-05-09
EVENT
Scroll to Top